| TA96 |
Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a (TA96) |
|
-
-
Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B
NICE has made the following recommendations about the use of adefovir dipivoxil and peginterferon alfa-2a to treat chronic hepatitis B. These recommendations do not apply to people who are also infected with hepatitis C or D, or HIV.
Peginterferon alfa-2a is recommended as a possible first treatment for adults with chronic hepatitis B, as long as it is suitable for the person and the exact type of hepatitis B they have.
Adefovir dipivoxil is recommended as a possible treatment for a person with chronic hepatitis B as long as it is suitable for the person and the exact type of hepatitis B they have. And if:
- treatment with peginterferon alfa-2a or another interferon called interferon alfa has not worked for that person, or
- treatment with an interferon worked at first, but the person has had a relapse, or
- the person can‘t take peginterferon alfa-2a or interferon alfa, or has had serious side effects from taking these medicines.
Adefovir dipivoxil should not normally be given before the person has had lamivudine treatment. It may be given – on its own or with lamivudine – when:
- the person’s hepatitis B virus has become resistant to lamivudine, or
- the virus is likely to become resistant to lamivudine quickly and the resistance could cause problems for the person, such as serious liver disease.
NICE has recommended that treatment with peginterferon alfa-2a or adefovir dipivoxil should be started only by a doctor who specialises in treating viral hepatitis. This specialist may then set up an arrangement so that the person’s GP can continue prescribing the medicine, with advice and guidance from the specialist (this is called a shared-care arrangement).
-
Other information
How this guidance was produced
Background information
- Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a: review decison - October 2011
- Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a: review proposal - July 2011
- Review decision: June 2009
- Review proposal: May 2009
- Review decision, October 2007
- Review proposal, July 2007
- Assessment report: Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a
- People with chronic hepatitis B to benefit from guidance on new drugs and treatments
- Appendix A
- Appendix A - matrix of consultees and commentators
- Appendix 1: Proposal comment summary table
This page was last updated: 13 December 2011
-
Guidance formats
Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a
Guideline for patients and carers (PDF)
-
Implementation tools and resources
- Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a: analysis of cost impact
- TA96 Drug treatment for chronic hepatitis B: slide set
See this guidance in practice
Patient
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
NICE Guidance
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
Full Guidance
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.
